| Condition | Key Finding | Association | Board Exam Tip |
| Agoraphobia | Fear of public/open spaces | Panic attacks, inability to leave home | Focus on situation avoidance, not just social fear (Social Anxiety). |
| Patent Foramen Ovale (PFO) | Right-to-left shunt; Bubble study positive | Cryptogenic stroke, DVT -> PE risk | The link between right heart emboli and left systemic circulation is key. |
| Methotrexate Pneumonitis | Interstitial lung disease; Dry cough | Anti-cancer agent toxicity | Always consider drug etiology when pulmonary fibrosis/cough is presented. |
| Osteogenesis Imperfecta (OI) | Blue sclerae, recurrent fractures | Type I collagen defect | The most common associated complication tested is conductive hearing loss (audiography). |
| Medical Decision Making | Incapacity; No POA | Hierarchy: Designated -> Family -> Friend | Always follow the established legal/ethical hierarchy. |
| Topic | Key Point | Context | Exam Relevance |
| Anxiety Disorders | Agoraphobia vs Social Anxiety | Fear of public spaces (Agoraphobia) vs fear of social interaction (Social Anxiety). | The question emphasizes the most prominent source of fear/avoidance. |
| Stroke Workup | PFO Diagnosis | Echocardiogram with bubble study is required to detect right-to-left shunting. | Essential for linking DVT/atrial thrombi to systemic emboli (cryptogenic stroke). |
| Pulmonary Fibrosis | Drug Culprits | Methotrexate, Amiodarone, Nitrates, etc. | Test questions often use unusual drug associations to test deep knowledge. |
| OI Screening | Associated Complication | Type I collagen defect affects middle ear ossicles (conductive hearing loss). | Do not assume the screening must relate directly to bone density or calcium metabolism. |
| Board-speak / Vignette phrase | Diagnosis / Concept | Why it fits |
| "Fear of being in public places, open spaces, or crowds" leading to avoidance behavior. | Agoraphobia | The core fear is related to the situation (being outside/in public), not just social interaction. |
| Young patient with stroke symptoms and no clear cardioembolic source; DVT present. | Cryptogenic Stroke / PFO | Suggests a right-to-left shunt allowing venous emboli (from DVT) to enter the systemic circulation, causing an MCA infarct. |
| Progressive dyspnea and bilateral fine crackles in a patient on Methotrexate. | Drug-induced Interstitial Lung Disease | Methotrexate is a classic culprit for pneumonitis/fibrosis; recognizing drug associations is high yield. |
| Blue sclerae and recurrent fractures in childhood. | Osteogenesis Imperfecta (OI) | OI is a Type I collagen defect, leading to bone fragility and characteristic blue discoloration of the sclera due to thin overlying tissue. |
| Incapacitated patient with no DHCPOA; son lives out of state but speaks daily. | Close Family Member (Son) | Following the ethical hierarchy: Son is the closest family member available for decision-making authority. |
| Key Features | Distinguishing Findings | Next Step |
| Evidence of right-to-left shunting; unexplained stroke in young patient. | DVT present, but no clear source (e.g., atrial fibrillation). | Echocardiography with bubble study to confirm PFO/ASD. |
| Stroke associated with known cardiac arrhythmia (e.g., A Fib). | Clear embolic source from the heart atrium. | Anticoagulation (Warfarin, DOA Cs) and potential LAA closure device. |
| Key Features | Distinguishing Findings | Next Step |
| Patient has pre-designated agent for care. | Legal document exists (DHCPOA). | Follow the wishes of the designated agent regardless of family relationship. |
| No POA; close family member is available and capable. | Family consensus/relationship strength. | Consult with the immediate, closest surviving family members. |
| No clear family or designation; friend has known history. | Long-term, trusted non-family confidante. | Use the best judgment of the medical team in consultation with the friend. |
🚨The classic triad for OI is bone fragility, blue sclerae, and hearing loss; the underlying defect is in Type I collagen.
| Condition | Association | Mechanism | Clinical Significance |
| Agoraphobia | Panic attacks, avoidance behavior | Fear of situations where escape might be difficult or help unavailable. | Requires comprehensive behavioral therapy (CBT) and often SSR Is; not just a fear of crowds. |
| Patent Foramen Ovale (PFO) | Cryptogenic stroke, DVT -> MCA infarct | Right-to-left shunt allows venous emboli to bypass the pulmonary circulation into systemic arteries. | Requires echo with bubble study for diagnosis; risk stratification is key. |
| Osteogenesis Imperfecta (OI) | Conductive hearing loss | Type I collagen defect affects middle ear ossicles (malleus, incus, stapes). | Audiography is the most appropriate screening test, not bone density scans or retinal exams. |
| Methotrexate Pneumonitis | Interstitial Lung Disease | Drug-induced inflammation/fibrosis of the lung parenchyma. | Always consider drug toxicity when pulmonary fibrosis presents in a patient on chronic therapy. |
| Term | Definition | Context | Example |
| Agoraphobia | Anxiety disorder characterized by fear and avoidance of situations where escape might be difficult or help unavailable. | Mental health diagnosis; differentiating from GAD/Social Anxiety Disorder. | Fear of using public transportation, large crowds, or being outside the home. |
| PFO (Patent Foramen Ovale) | A persistent opening between the right and left atria in the heart that fails to close after birth. | Cardiology workup for unexplained stroke; linking DVT/atrial thrombi to systemic emboli. | Diagnosed via echocardiogram with bubble study, suggesting a risk of cryptogenic embolism. |
| Methotrexate Pneumonitis | Drug-induced interstitial lung disease (ILD). | Toxicology/Pulmonology; recognizing drug side effects causing fibrosis or cough. | A patient on MTX for cancer develops progressive dyspnea and bilateral crackles. |
| Osteogenesis Imperfecta (OI) | Genetic disorder characterized by fragile bones, blue sclerae, and connective tissue defects. | Genetics/Orthopedics; understanding the systemic impact of collagen deficiency. | Screening must include audiography due to middle ear ossicle involvement. |
| Topic | Study Approach | Priority | Resources |
| Anxiety Disorders | Contextual Analysis | High | Review clinical vignettes, focusing on why one diagnosis is better than another (e.g., Agoraphobia vs GAD). |
| Stroke/Embolism | Linker Thinking | Critical | Practice linking peripheral sources (DVT) to distant targets (MCA stroke) via cardiac defects (PFO). |
| Ethics & Genetics | Hierarchy Recall | Medium-High | Memorize the decision-making hierarchy and the specific associated complications for genetic syndromes. |
🚫Mistake 1: Confusing Agoraphobia and Social Anxiety. Do not assume that because the patient had one social anxiety episode, they cannot have agoraphobia if their primary fear is public spaces generally. The scope of avoidance dictates the diagnosis.
🚫Mistake 2: Assuming Bone Density = Collagen Defect. OI is a defect in collagen synthesis (qualitative), not necessarily bone mineral density (quantitative). Therefore, Dexa scan is inappropriate.
⚠️Trap 1 (Anxiety): The question may include social anxiety elements to distract you from the primary, broader fear of public spaces (Agoraphobia). Focus on the most effort devoted by the vignette writer.
⚠️Trap 2 (Stroke): Including a DVT and stroke in a young patient is designed to make you think of PE/DVT workup; remember that PFO allows venous emboli from the right heart to reach the systemic circulation, causing an MCA infarct.
⚠️Trap 3 (OI): The blue sclerae are merely a finding resulting from thin collagen, not the primary diagnostic feature or screening target. Focus on the most common associated complication: hearing loss.